Key facts
- It has raised $1.1M; the latest was Early Stage VC ($710K) in Dec 2024.
- Notable investors include Tech Incubator Program for Startup, Center for Creative Economy and Innovation, Korea Technology Finance, Y&Archer, Agricultural Policy Insurance and Finance Institute — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Bichedam
- ·The full record, as it builds
Funding rounds
No funding rounds for Bichedam are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bichedam
Developer of an antihypertensive treatment based on the herbal ingredient designed to supplement problems such as dizziness and chest tightness. The company aims to cure dizziness and chest tightness that can occur from long-term use of antihypertensive drugs through a herbal antihypertensive drug, enabling hypertensive patients to cure their diseases.
- Sector
- Healthcare
- HQ
- Gyeongsan, South Korea
- Founded
- 2022
- Ownership
- Privately Held (backing)
Bichedam doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bichedam shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bichedam in its N-PORT filings yet. We sweep new filings monthly.